Gilead secures new anti-cancer therapy in $4.9bn deal
02-03-2020
Sundry Photography / Shutterstock.com
Gilead Sciences has unveiled an agreement with Jounce Therapeutics to exclusively develop and license its antibody programme, JTX-1811, which is designed to fight cancer cells.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Gilead, Jounce Therapeutics, cancer treatment, JTX-1811, agreement, equity investment, IND, tumours, immunotherapy, antitrust, royalties, oncology
